Whether a development team is proposing a new internal tool or presenting a potential product for a customer, a proof of concept is a critical early step for validating that the team fully grasps the ...

SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and ...

The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

NEW YORK--(BUSINESS WIRE)--Neurogene, Inc., a company with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced that researchers ...

LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy ...

LAWRENCEVILLE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, announces that Khursheed Anwer, Ph.D ...

For the federal government to move beyond isolated AI experiments, agencies must adopt an "AI factory" model that securely ...

The European Conference on Interventional Oncology (ECIO) is renowned as the most comprehensive platform for interventional oncology education and knowledge sharing - bringing together a growing ...

BOSTON and LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a range of interim clinical outcomes, in addition to the ...

Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...

The NEUROFUSE Study is an ongoing 48-week Multicenter, Randomized, evaluator-blinded, Phase 2a study in upper extremity nerve transections comparing NTX-001 adjunctive to standard of care (SOC) to SOC ...